Intelligence / Healthtech & medtech / Market map
Healthtech & medtech market map
The healthtech and medtech industry supplies medical devices, diagnostics, digital health, health IT, and life-science tools and services to business buyers. Buyers include hospitals and health systems, physician practices, ambulatory and alternative-care sites, pharmaceutical and biotech companies, life-science laboratories, contract research and manufacturing organisations, and public or private payers; the buying decision typically involves clinical, procurement, IT, finance, and regulatory stakeholders.
The map
Sectors sized by their share of the market; tiles are submarkets, coloured by attractiveness for B2B sellers. Click any block.
Where to play
Every submarket by size and attractiveness (pain × purchasing power × reachability × growth).
Distribution, channel and commercial infrastructureLife-science tools, instruments and laboratory servicesDiagnostics and laboratory productsDigital health software and connected health technologyClinical and regulatory support servicesDeployment, integration and lifecycle services · Bubble size = growth (CAGR)
Analyst's view
For B2B sellers this is a large, device-weighted market: roughly 57% of the pool sits in medical devices, with surgical/interventional, therapeutic and monitoring use cases carrying the money, and a further 18% in life-science tools, instruments and reagents where recurring consumables revenue is the most defensible annuity. The pain and the budget sit with hospital and lab procurement — capital equipment cycles, tendering, and the consumables and service tail that follows installation — which is why channel, deployment and lifecycle nodes matter even though they are currently sized as rounding errors. The map's weakest areas are the digital-health and diagnostics subtrees, which are understated and overlap with device nodes, and the absence of any buyer-side cut (IDNs, ambulatory groups, pharma and medtech sponsors) that would let a seller target a specific budget owner.
- Rising adoption of AI-enabled diagnostics, robotics, and other differentiated technologies is increasing innovation and investment across MedTech [1][2]
- Expansion of MedTech into alternative care settings creates new procurement demand outside traditional hospital channels [2]
- Continued outsourcing and investment in clinical development, laboratory workflows, and life-science tools support demand for research products and services [2]
- Digital transformation, interoperability, remote monitoring, and care-delivery efficiency requirements drive health IT and digital-health procurement [2]
- European medtech employment above 950,000 and record patent filings indicate continued product development and innovation capacity [3][5]
- Growth in diabetes care, minimally invasive therapies, structural heart, and other chronic-disease management areas expands device and diagnostic demand [2]
- Europe's medtech market grew only 1.8% in 2025, well below its roughly 6% decade average, indicating slow underlying demand growth [3][5][6]
- Europe's share of the global medtech market fell to 25.6% from 26.4%, suggesting relative share loss to faster-growing markets [3][5][6]
- The number of public MedTech companies in the US and Europe fell another 17% in 2025, reflecting consolidation and pressure on non-leading companies [1]
- Tariff uncertainty, trade headwinds, and macroeconomic uncertainty constrain capital budgets and slow purchasing decisions [9]
- A two-tier industry structure concentrates growth and value in high-performing, high-differentiation innovators, making it harder for undifferentiated suppliers to win [1]
- Regulatory approval, clinical validation, reimbursement, and evidence requirements lengthen sales cycles and raise selling costs
All segments 160
Sizes in USD, latest available year. Confidence reflects the sources behind each figure.
// From map to pipeline
AOS turns the most attractive niches into accounts with a reason to talk now, and prepares the outreach for your approval.
Researched by the AOS market intelligence agent from public sources; refreshed weekly. Figures are estimates with stated methods and confidence, not investment advice.